Quantcast

Latest leukemia Stories

2014-10-30 12:29:56

HOUSTON, Oct. 30, 2014 /PRNewswire-USNewswire/ -- Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs, and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of The University of Texas MD Anderson Cancer Center's Moon Shots Program. First-of-a-kind combination clinical trials; advanced molecular analysis to guide treatment and screening; and a focused program to gather, store, access...

2014-10-30 04:20:57

AMSTERDAM, October 30, 2014 /PRNewswire/ -- Kiadis Pharma B.V. ("Kiadis Pharma" or "the Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR(TM) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML). Kiadis Pharma has previously been granted an ODD for ATIR(TM) by both the EMA and the FDA for...

2014-10-29 08:34:22

This Year Marks the 20th Anniversary of LLS's Prestigious Translational Research Program WHITE PLAINS, N.Y., Oct. 29, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) is awarding $15.6 million in academic grants to 26 scientists who have proposed innovative laboratory research that shows promise in leading to new treatments for blood cancer patients. The funds are being awarded through LLS's Translational Research Program (TRP), which aims to accelerate...

2014-10-28 12:31:13

The Program is Jointly Funded by LLS and Janssen Research & Development, LLC WHITE PLAINS, N.Y., Oct. 28, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society has initiated a program to fund research projects seeking to better understand and, ultimately, stop progression of certain types of blood cancers from early-stage malignancies to much more lethal states of disease. The types of early-stage blood cancers the program will focus on are the "myeloid" diseases, such...

2014-10-27 04:21:55

- Tosedostat Currently in Phase 2 Development for Patients with AML and MDS - SEATTLE, Oct. 27, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited (Vernalis), the originator of tosedostat, and Chroma Therapeutics Ltd. (Chroma), through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America....

2014-10-23 08:34:28

Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility...

2014-10-21 12:32:21

WHITE PLAINS, N.Y., Oct. 21, 2014 /PRNewswire-USNewswire/ -- For the second year, The Leukemia & Lymphoma Society (LLS) will award funding to leading scientists and researchers who show promise in developing new drug therapies through the Screen to Lead Program. The collaborative program aims to support academic laboratories pursuing research directed towards medicinal chemistry and/or drug target screening in blood cancers. Members of a peer review panel select projects for...

2014-10-20 16:27:17

WHITE PLAINS, N.Y., Oct. 20, 2014 /PRNewswire-USNewswire/ -- Six academic investigators will receive grants from The Leukemia & Lymphoma Society (LLS) to support innovative ideas that that have the potential to take research in a new direction and fundamentally impact the future of blood cancer diagnosis and treatment. The second-year grant program, called The New Idea Award, looks to identify novel research strategies that involve the exploration of untested but potentially...

2014-10-20 08:31:48

Filing completed just three months after receipt of third FDA approval SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on data from a Phase 2 study evaluating the use of IMBRUVICA(®) (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM), which was led by Dr. Steven Treon from the Dana-Farber Cancer...

2014-10-17 08:25:55

SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the European Commission (EC) has granted marketing approval for IMBRUVICA(®) (ibrutinib) throughout the 28 member states of the European Union (EU). IMBRUVICA, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to be marketed in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with...


Latest leukemia Reference Libraries

Clinical Leukemia
2012-05-18 15:34:28

Clinical Leukemia is a peer-reviewed medical journal published by CIG Media Group. The journal publishes articles on detection, diagnosis, prevention, and treatment of leukemia. The main emphasis is on recent scientific developments in all areas related to leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance, gene and antisense therapy; pathology, markers, and prognostic indicators, chemoprevention strategies,...

More Articles (1 articles) »
Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.